Sai Parenteral's to own SP Analytics outright for Rs 25,000

Sai Parenteral's Limited plans to pay Rs 25,000 in cash for the final 25% of SP Analytics Private Limited, raising its holding from 75% to 100%. The board approved the purchase on November 1, 2026, and the pharma-testing subsidiary reported nil turnover during the last three financial years. Completion is indicated by December 31, 2026.

How will Sai Parenteral's ownership of SP Analytics change?

Sai Parenteral's will acquire the remaining 25% equity holding in SP Analytics, taking its ownership from 75% to 100% on completion. The board considered and approved the proposal at its November 1, 2026 meeting, describing SP Analytics as an existing subsidiary that would become wholly owned after the transaction.

The proposed purchase covers 2,500 equity shares with a face value of Rs 10 each. The announcement identifies the stake as the final 25% of SP Analytics, so the disclosed ownership change is the removal of the remaining outside interest rather than the acquisition of a new subsidiary.

The company has not stated the identity of the seller or the date on which it obtained the existing 75% holding. It has, however, specified that the 2,500 shares will be acquired for cash and that SP Analytics will be wholly owned once the transfer is completed.

How much will Sai Parenteral's pay for SP Analytics?

Sai Parenteral's will pay Rs 25,000 in cash to acquire the 2,500 shares representing SP Analytics' remaining 25% equity stake. The disclosure identifies cash as the form of consideration, rather than a share swap or another payment method.

The stated acquisition price is Rs 25,000, while the acquired shares have an aggregate face value of Rs 25,000 at Rs 10 each. The filing does not provide a valuation report, asset value, earnings measure, or other numerical basis for the agreed consideration.

Sai Parenteral's says the transaction is proposed to be conducted at arm's length on terms mutually agreed by the parties, supported by an appropriate assessment wherever applicable. The company does not disclose the payment date, source of the cash, or whether the Rs 25,000 consideration is subject to conditions before the indicated December 31, 2026 completion deadline.

What does SP Analytics do and what turnover has it reported?

SP Analytics was incorporated on November 16, 2023, with the main object of testing, analysing and examining pharmaceuticals, medicines, drugs and related materials. Sai Parenteral's categorises the target within the pharma sector in its acquisition disclosure.

SP Analytics reported nil turnover in each of the last three financial years, according to Sai Parenteral's. Turnover therefore remained unchanged at nil across the three periods cited, even as Sai Parenteral's proposes to pay Rs 25,000 for the final 25% stake.

The filing provides no yearly turnover break-up, profit or loss figure, customer information, testing capacity, employee count, or asset base for SP Analytics. It also does not state whether the company has begun commercial operations since its November 2023 incorporation, beyond setting out its pharmaceutical-testing object.

Full ownership would consolidate an entity that is already 75%-owned rather than add a separately controlled business to Sai Parenteral's group. Sai Parenteral's has not quantified any expected revenue contribution, cost saving, laboratory capacity, or other financial effect from owning 100% of SP Analytics.

Is the SP Analytics purchase a related-party transaction?

Yes, Sai Parenteral's classifies the purchase as a related-party transaction, or RPT, under the Companies Act, 2013 and the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015. The company says SP Analytics is a related party and that its promoters or promoter group have an interest in the entity because of their relationship with it.

Sai Parenteral's states that the Rs 25,000 transaction is proposed to be at arm's length, based on mutually agreed terms and conditions and supported by an appropriate assessment wherever applicable. The filing does not identify the individual promoters or promoter-group entities with an interest, or quantify their holdings in SP Analytics.

The related-party classification applies to the purchase of the last 25% in a subsidiary already held at 75% by Sai Parenteral's. The company says no governmental or regulatory approvals are required, but the disclosure does not state whether any further internal approval or shareholder approval will be sought before the December 31, 2026 target date.

When is Sai Parenteral's expected to complete the purchase?

Sai Parenteral's has set an indicative completion period of on or before December 31, 2026. Its board approval on November 1, 2026 authorises the proposed cash acquisition, but the announcement does not say that the 2,500-share transfer had been completed on the date of the filing.

Once completed, the transaction will change SP Analytics from a 75%-owned subsidiary to a wholly owned subsidiary. The company separately disclosed on November 1, 2026 that it had completed the acquisition of 60% of Saicriti Pharma Private Limited after board approval on August 11, 2026, but it has not linked that completed acquisition to the Rs 25,000 SP Analytics transaction.

The SP Analytics disclosure gives a defined ownership target of 100% and a completion date of December 31, 2026. It does not disclose an expected post-completion merger, operational integration, additional investment, or financial target for the pharmaceutical-testing subsidiary.

Conclusion

Sai Parenteral's is seeking to convert SP Analytics into a wholly owned subsidiary through a Rs 25,000 cash purchase of the final 25% stake. The deal concerns a pharma-testing company incorporated in November 2023 that reported nil turnover across the last three financial years, and it is classified as a related-party transaction.

The next disclosed event is completion on or before December 31, 2026. Investors should watch for confirmation that the 2,500 shares have transferred and for any later disclosure on SP Analytics' operations, financial contribution, or the assessment supporting the agreed consideration.